The team
Vidar Wendel-Hansen
Chief Exectutive Officer
MD, PhD
Vidar Wendel-Hansen has more than twenty years’ experience from pre-clinical and clinical development. He has served as Medical Director in both small biotech and large pharmaceutical companies. Dr Wendel-Hansen is also former Clinical Assessor at the Swedish Medical Products Agency.
Jonas Ekblom
Business Advisor
PhD
Jonas Ekblom has over 25 years of experience from pharmaceutical R&D. Dr. Ekblom has held senior positions at Pharmacia, Sequenom, Life Technologies, and BOWS Pharmaceuticals. Dr. Ekblom is the CEO of Promore Pharma AB. Jonas Ekblom also serves of the board of several other organizations including EffRx Pharmaceuticals SA, Med-C, and The Releef Initiative.
Anette Wärnmark Carr
Chief Scientific Officer
MSE, PhD
Anette has over 20 years’ experience of project management and solution oriented work, both as Senior Scientist at Karolinska Institutet and in the pharmaceutical industry.
She has experience from both small and big pharmaceutical companies in the areas of discovery, pre-clinical, and CMC.
She holds a MSE in Chemistry from the Royal Institute of Technology (KTH) and a PhD in Cell and Molecular Biology from the Karolinska Institutet.
Aleksandra Liverts
Office Manager
BA, MOH
Alexandra has more than 10 years of professional experience from research administration including roles as administration officer, program coordinator and project manager within the Israeli academic system. She holds a B.A. in Health Systems Management from Ben-Gurion University of the Negev, and a Master in Occupational Health from Tel Aviv University.
Ann-Sofie Sternås
Senior Patent Attorney EPA, Director Intellectual Property
(European Patent Attorney, MSc Chemical Engineering)
Ann-Sofie Sternås has almost 20 years of IP experience from large pharmaceutical companies and has held senior IPR positions within Astra and AstraZeneca. For many years, Ms. Sternås was heavily involved in IP litigation relating to several blockbuster drugs. Ms. Sternås is specialized in IP-strategic matters with a heavy focus on US legislation, particularly IP in the interface between patent law and regulatory law.